⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 7, 2021EyeOpen Access

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD

Usha Chakravarthy Moshe Havilio Annie Syntosi Natasha Pillai Emily Wilkes Gidi Benyamini Catherine Best Alexandros Sagkriotis

View Full Paper

Ask AI

Bookmark

Share

Abstract

Greater fluctuations in retinal fluid volumes during the maintenance phase of anti-VEGF treatment in nAMD is associated with worse VA by 2 years.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chakravarthy et al. (2021) studied this question.

synapsesocial.com/papers/69d7f8f15c3030ff03d189c7 https://doi.org/10.1038/s41433-020-01354-4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Hydrus microstent combined with cataract surgery or used alone: cost-utility analysis for UKEye · 2026
2Pneumatic retinopexy identification in electronic medical records using an on-premises large language modelEye · 2026
3Large language models as internal consistency checkers for ophthalmic manuscriptsEye · 2026
4Prelaminar hyperreflective lines in non-arteritic anterior ischaemic optic neuropathyEye · 2026
5Deep learning–based prediction of one-year functional and structural outcomes in treatment-naïve DMO after anti-VEGF therapyEye · 2026

Systematic review of eyecare Patient-Reported Experience Measures (PREMs) following COSMIN guidelinesEye · 2026
A scoping review of integrated blink analysis technologies for ocular surface diseasesEye · 2026
Risk factors, microbiological profiles, and clinical outcomes of paediatric infectious keratitis: The Midlands Infectious Keratitis StudyEye · 2026
Cognitive heuristics in the operating room: the role of ‘left-digit bias’ in ophthalmic surgical selectionEye · 2026
Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degenerationEye · 2026

More from Novartis (Switzerland)

More from Queen's University Belfast

More from IQVIA (United Kingdom)

More from Notal Vision (Israel)